semaglutide gastrointestinal obstruction class action in michigan glp-1 gastric intestinal Association of receptor agonists with risk of patients with type 2 diabetes mellitus: a glp-1 gastric intestinal obstruction class

Only a licensed clinician may prescribe this drug for this condition if in their clinical judgment use of the product is medically appropriate

Reproductive gains as hypothesis-generating findings: while favorable exploratory findings are observed in outcomes such as menstrual regularity, androgenic markers, and natural conception/TTP, these findings are generally limited by small sample sizes, restricted follow-up windows, and a lack of gold-standard ovulatory measurements

According to a recent press release, tirzepatide was non-inferior to dulaglutide, an agent with proven cardiovascular prevention benefits, in preventing MACE-3, defined as cardiovascular death, nonfatal heart attack, or nonfatal stroke

In November 2023, a new GLP-1, called tirzepatide (Zepbound, Mounjaro), was approved for weight loss and obesity management

Availability note: Medication availability and Health Canada approvals can change over time

1030 Jang, H